Prevention and treatment of drug-resistant tuberculosis

American Journal of Health-System Pharmacy

Volumn 53, Issue 19, 1996, Pages 2291-2298

  Humma, Larisa M ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Aminosalicylic acid; Antituberculars; Capreomycin; Ciprofloxacin; Combined therapy; Compliance; Cyclosporine; Ethambutol; Ethionamide; HIV infections; Isoniazid; Mycobacterium tuberculosis; Ofloxacin; Protocols; Pyrazinamide; Quinolones; Resistance; Rifampin; Streptomycin; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; CHEMOPROPHYLAXIS; CLINICAL PROTOCOL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SPUTUM CULTURE; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0029821177     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.19.2291     Document Type: Review

References (40)

1. Jereb JA, Kelly GD, Dooley SW et al. Tuberculosis morbidity in the United States: final data, 1990. MMWR. 1991; 40(SS-3):23-7.
2. Centers for Disease Control. Meeting the challenge of multidrug-resistant tuberculosis: summary of a conference. MMWR. 1992; 41(RR-11):51-7.
3. Curtis JR, Hooton TM, Nolan CM. New developments in tuberculosis and HIV infection: an opportunity for prevention. J Gen Intern Med. 1994; 9:286-94.
4. Bloch AB, Cauthen GM, Onorato IM et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA. 1994; 271:665-71.
5. Centers for Disease Control. A strategic plan for the elimination of tuberculosis in the United States. MMWR. 1989; 38(S-3):1-25.
6. Kent JH. The epidemiology of multidrug-resistant tuberculosis in the United States. Med Clin North Am. 1993; 77:1391-409.
7. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med. 1994; 149:1359-74.
8. Centers for Disease Control. National action plan to combat multidrug-resistant tuberculosis. MMWR. 1992; 41(RR-11):1-48.
9. Fischl MA, Uttamchandani RB, Daikos GL et al. An outbreak of tuberculosis caused by multiple-drug resistant tubercle bacilli among patients with HIV infection. Ann Intern Med. 1992; 117:177-83.
10. Small PM, Shafer RW, Hopewell PC et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med. 1993; 328:1137-44.
11. Centers for Disease Control and Prevention. Screening for tuberculosis and tuberculosis infection in high risk populations. MMWR. 1995; 44(RR-11):19-34.
12. Peloquin CA. Mycobacterial infections. Pharmacotherapy. 1993; 13:634-9.
13. Bloch AB, Onorato IM, Castro KG. Multiple-antibiotic-resistant bacteria. N Engl J Med. 1994; 331:678-9. Letter.
14. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993; 329:784-91.
15. Mandell GL, Sande MA. Antimicrobial agents, drugs used in the chemotherapy of tuberculosis and leprosy. In: Gilman AG, Goodman LS, Rall TW et al., eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Macmillan; 1985:1199-218.
16. Reichman LB. Multidrug-resistant tuberculosis: meeting the challenge. Hosp Pract. 1994; 29:85-8,91,95-6.
17. Goble M, Iseman MD, Madsen LA et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993; 328:527-32.
18. Telzak EE, Sepkowitz K, Alpert P et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med. 1995; 333:907-11.
19. Kennedy N, Fox R, Kisyombe GM et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis. 1993; 148:1547-51.
20. Kohno S, Koga H, Kaku M et al. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest. 1992; 102:1815-8.
21. Berning SE, Madsen L, Iseman MD et al. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J Respir Crit Care Med. 1995; 151:2006-9.
22. Kennedy N, Fox R, Uiso L et al. Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis. J Antimicrob Chemother. 1993; 32:897-902.
23. Yew WW, Wong CF, Wong PC et al. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin. Clin Infect Dis. 1993; 17:288-9. Letter.
24. Cynamon MH, Palmer GS. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1983; 24:429-31.
25. Yew WW, Wong CF, Lee J et al. Do β-lactarn-β-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis? Tuber Lung Dis. 1995; 76:90-2.
26. Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampin. Tuber Lung Dis. 1993; 73:59-67.
27. Cavalieri SJ, Biehle JR, Sanders WE. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995; 39:1542-5.
28. Weis SE, Slocum PC, Biais FX et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994; 330:1179-84.
29. Gostin LO. Controlling the resurgent tuberculosis epidemic. A 50-state survey of TB statutes and proposals for reform. JAMA. 1993; 269:255-61.
30. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis. We can't afford not to try it. N Engl J Med. 1993; 328:576-8.
31. Centers for Disease Control. Management of persons exposed to multidrug-resistant tuberculosis. MMWR. 1992; 41(RR-11):59-71.
32. Heifets LB. Expedited detection of drug resistance in tuberculosis patients. Ann Emerg Med. 1994; 24:457-61.
33. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis. 1989; 140:1189-93.
34. Horn DL, Hewlett D, Alfalla C et al. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med. 1994; 330:1241. Letter.
35. Passannante MR, Gallagher CT, Reichman LB. Preventive therapy for contacts of multidrug-resistant tuberculosis. A delphi survey. Chest. 1994; 106:431-4.
36. Stevens JP, Daniel TM. Chemoprophylaxis of multidrug-resistant tuberculous infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide. A decision analysis. Chest. 1995; 108:712-7.
37. Centers for Disease Control and Prevention. Tuberculosis morbidity - United States, 1994. MMWR. 1995; 44:387-95.
38. CDC efforts reflect concern about drug-resistant TB. Am J Hosp Pharm. 1994; 51:448-9,452. News.
39. Centers for Disease Control. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR. 1989; 38:236-50.
40. Barnes PF, Le HQ, Davidson PT. Tuberculosis in patients with HIV infection. Med Clin North. Am. 1993; 77:1369-90.